Year: 2025

Ra’anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced new results from its ongoing preclinical evaluation of its proprietary intranasal naloxone hydrogel formulation, demonstrating promising permeation kinetics that complement the Company’s previously reported stability and mucoadhesion successes. Following the positive mucoadhesion findings-where Polyrizon’s formulation showed significantly enhanced persistence on ex-vivo nasal tissue compared to a marketed intranasal naloxone product (p < 0.0001) -the Company has completed a dedicated series of permeation studies using a validated artificial membrane system. These studies assessed the rate and extent of naloxone diffusion from...

TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Silver Trust (NYSE: PSLV) (TSX: PSLV / PSLV.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical silver bullion, today announced that the Trust has updated its at-the-market equity program (“ATM Program”) to issue an additional U.S.$1 billion of units of the Trust (“Units”) in the United States and Canada pursuant to a prospectus supplement dated December 11, 2025 (the “Prospectus Supplement”) to the short form base shelf prospectus dated May 1, 2025 (the “Base Shelf Prospectus”). Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on EDGAR at the SEC’s website at www.sec.gov...

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responsesPromising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in the tumor-agnostic setting of advanced PRAME cancers beyond melanoma, starting with gynecologic cancersDose escalation and determination of RP2D on track to be completed in 2026, including data on two highest dose levelsHouston, Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical...

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseResults show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s disease Clear safety profile with no clinically relevant safety issues reported Targets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessments Underlines potential and importance of active immunotherapies in precision medicine for neurodegenerative diseases AC Immune to host webcast and conference call today at 9:00am ET / 15:00 CET details belowLausanne, Switzerland, December 11, 2025 — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative...

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.1 The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The study included 76 eyes from patients with moderate to advanced glaucoma...

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, announced today that George Magrath, M.D., Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT. A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. The Company is developing durable, one-time treatments designed to address...

Project will test the use of plasma in the recovery of critical minerals from end-of-life batteries MONTREAL, Dec. 11, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of a contract with a company engaged in large-scale battery recycling, for the testing of high-temperature plasma during the material recovery and new battery production process. The client is one of the largest of its kind in the world. The client’s name and the total value of the project are being withheld for competitive and confidentiality reasons. PROJECT HIGHLIGHTS Purpose: using plasma to replace fossil fuel heating during lithium-ion...

TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, announces the launch of Amped Live Resin Liquid Diamond 1g 510 cartridges, marking Redecan’s first live resin–liquid diamond line for the brand. The debut lineup, Space Age CK and Blueberry DNTS, pairs Redecan’s Legit Live Resin with Liquid Diamonds to deliver a true‑to‑strain flavour and aroma in a performance‑engineered 510 vape cartridge. Amped was developed to preserve what we believe consumers value most in live resin: full‑spectrum cannabinoids and strain‑specific terpenes that reflect the plant’s authentic profile. By formulating with 80% Legit Live Resin™ and 20% Liquid Diamonds, Amped enhances...